Aptorum Group Announces Clinical Validation Update of its Liquid Biopsy Infectious Disease Detection RPIDD Technology

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-phase biopharmaceutical company focused on innovative technologies for the treatment and diagnosis of infectious diseases, announces that its subsidiary Aptorum Innovations Holding Limited (“Aptorum Innovations”) has initiated clinical validation of its liquid biopsy rapid pathogen diagnostic molecular technology (“RPIDD”) for the diagnosis of pathogens, including viruses, bacteria, fungi and parasites.

Aptorum Innovations is pleased to announce that as part of ongoing clinical validations in Singapore for RPIDD technology, 12 patients have been enrolled, who have febrile neutropenia and septic conditions, and that more than 53 samples have been collected. and analyzed. Several bacteria and viruses were detected in samples from these patients, including Escherichia coli, Klebsiella pneumoniae and Herpesviridae. The data were cross-validated by standard diagnostic results, such as blood culture technology. RPIDD achieved the sensitivity and analytical specificity of spicular samples capped at 100% and 90% respectively, in both shallow (60,000 reads) and high depth (1 million reads) sequencing. RPIDD will continue to be validated during 2022, in parallel with its pre-market process in 2022.

Mr. Ian Huen, CEO and Executive Director of Aptorum Group: “We are very pleased to announce this important update on our RPIDD technology. The high sensitivity and specificity demonstrated so far supports our goal of delivering technology through Rapid, accurate and cost-effective liquid biopsy for the diagnosis of infectious diseases. We hope that RPIDD will revolutionize traditional approaches to first-line clinical diagnosis, which are time-consuming and fail to detect and identify disease-causing pathogens. ‘a rapid molecular diagnostic approach for infectious diseases will significantly reduce mortality and morbidity. In 2022, we will launch the pre-market processes for our RPIDD technology, including the identification of clinical partners to support its deployment.”

About Aptorum’s Rapid Pathogen Identification and Detection (RPIDD) technology

RPIDD is an innovative rapid molecular diagnostic technology for the detection of pathogens by liquid biopsy. Proprietary technologies are under development to enrich pathogenic DNA / RNA for analyzes leveraging the power of next-generation sequencing platforms and proprietary AI-based software analyzes with the goal of rapidly identifying and detecting any foreign pathogen (viruses, bacteria, fungi, parasites) through its genomic composition and to identify other unknown pathogens and new mutated pathogens. RPIDD technology continues to be known to be validated in human samples and, so far, this type of test has detected pathogens (bacteria, fungi and viruses) with an objective approach. RPIDD is currently being validated in humans.

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic agents to treat diseases with unmet medical needs, in particular in oncology (including orphan indications in oncology) and infectious diseases. Aptorum’s pipeline is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutic actives through, for example, systematic screening of existing approved drug molecules, and a microbiome-based research platform for the treatment of metabolic diseases; and (ii) the co-development, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore Science, Technology and Research Agency, of innovative molecular technology to rapidly identify pathogens and perform screening diagnostics. .

For more information about Aptorum Group, please visit

Disclaimer and forward-looking statements

This press release does not constitute an offer to sell or a solicitation of offers to buy securities of Aptorum Group.

This press release contains statements concerning Aptorum Group Limited and its forecasts, plans and prospects for the future which constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. As such, all statements which contained in this press release and which are not statements of historical fact can be considered as forward-looking statements. In some cases, forward-looking statements can be identified by the use of terms such as “may”, “should”, “expects”, “plans”, “anticipates”, “may”, “intends” , “consider”, “plan”, “consider”, “believe”, “estimate”, “predict”, “potential” or “continue”, or the negative form of these or other similar terms. Aptorum Group has based these forward-looking statements, which include statements regarding expected timeframes for application submissions and testing, primarily on its current expectations and projections about future events and trends that the group believes could affect its operations. activities, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, but not limited to, risks associated with the announced changes to levels. management and organization, the retention and availability of key personnel, the ability of the company to expand its product lines by offering additional products in other consumer segments, the results of its development activities, the company’s planned growth strategies, anticipated trends and challenges in its business, expectations and stability of its supply chain, risks detailed on Form 20-F of Aptorum Group and in other documents that the Company may file with the SEC in the future, as well as in the prospectus received by the Autorité des marchés financiers in France (visa n ° 20-352) on July 16 2020. Accordingly, the expectations contained in such forward-looking statements are subject to change and actual results could differ materially from those described herein.

The Aptorum Group disclaims any obligation to update any forward-looking statements contained in this press release, whether in light of new information, future events or otherwise.

This publication does not constitute a prospectus within the meaning of regulation (EU) n ° 2017/1129 of June 14, 2017, as amended by delegated regulations (EU) n ° 2019/980 of March 14, 2019 and n ° 2019/979. of March 14, 2019.

This press release is provided “as is”, without representation or warranty of any kind.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.

Source link -88